share_log

HC Wainwright & Co. Downgrades Syros Pharmaceuticals to Neutral, Lowers Price Target to $1

Benzinga ·  Nov 13 19:54  · Ratings

HC Wainwright & Co. analyst Andrew Fein downgrades Syros Pharmaceuticals (NASDAQ:SYRS) from Buy to Neutral and lowers the price target from $6 to $1.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment